shutterstock_1843221310_maxshot_pl
MAXSHOT.PL / Shutterstock.com
23 May 2023FeaturesPharmaChad Landmon, Ross Blau and Gulrukh Haroon

Effects of GSK v Teva ripple after SCOTUS denies cert

Last week (May 15), the Supreme Court denied certiorari in GlaxoSmithKline v Teva Pharms USA (GSK v Teva), locking in the US Court of Appeals for the Federal Circuit’s second panel decision which held that Teva’s attempted section viii carve-out of an indication covered by a patented method of use was not ‘skinny’ enough to avoid being liable for infringement.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Week Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com 


More on this story

Pharma
12 November 2026   Handing the pharma giant a major win in its feud with Pfizer and BioNTech, the UPC’s injunction reaches well beyond the court’s member states. But with an appeal still possible and parallel disputes playing out across the US and Europe, the fight is far from over.
Pharma
12 November 2026   From GLP-1 drugs to cancer treatments, counterfeiters are exploiting supply chain weaknesses and AI to evade detection. The US chamber’s director of IP tells LSIPR why the fight against fakes is becoming more complex and what lies ahead.
Pharma
10 November 2026   The pharma giant has filed a trademark and passing off claim in London to try and prevent UK consumers from accessing fake weight-loss drugs and other prescription medicines, after its rival’s success in a similar claim earlier in 2026.